pharma news today obesity drugs glp-1 october 2025 GLP‑1 real‑world data for obesity: A new standard for metabolic care Dozens of new obesity drugs

Subgroup analysis for treatment durations6 months indicated a higher WL in the GLP-1RAs group (SMD=0.79, 95% CI 0.25 to 1.34)

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.

Form: Lyophilized White Powder

Learn about the latest science behind GLP-1 weight loss drugs, the nutritional needs of GLP-1 users and what this means for future innovation in food and beverage.

This article examines clinical safety data, GI mechanisms, and how genetic predispositions may influence medication tolerance in IBD patients see

If approved, it will certainly bea case of profoundly delayed gratification. Tough for me not see some level of sour grapes here indeed, the process of drug discovery is complex, long and riddled with failures we now have the amazing biotechnology advances of liraglutide, semaglutide, tirzetapide, and many more to come, that should be celebrated for the millions, to over a billion lives, that can be improved across the world